-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Reiterates Outperform on BridgeBio Oncology, Maintains $25 Price Target

Benzinga·12/11/2025 14:28:58
Listen to the news
Wedbush analyst David Nierengarten reiterates BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and maintains $25 price target.